1. Vitry, J.; Paré, G.; Murru,A.; Charest-Morin, X.; Maaroufi, H.;McLeish, K.R.; Naccache, P.H.;Fernandes, M.J. Regulation of the Expression, Oligomerisation and Signaling of the Inhibitory Receptor CLEC12A by Cysteine Residues in the Stalk Region. Int. J. Mol. Sci. 2021,22, 10207.
Clec12a (also called myeloid inhibitory C-type lectin-like receptor, MICL) was originally described as an ITIM-containing inhibitory CLR expressed by human granulocytes and monocytes. It was suggested that Clec12a recognizes some endogenous ligands as soluble Clec12a could bind to single-cell suspensions isolated from various murine tissues. CLEC12A is a myeloid lineage antigen that is highly expressed by AML cells and LSCs, but not expressed by normal hematopoietic stem cells (HSCs), thus minimizing off-target toxicity.
1μg (R: reducing condition, N: non-reducing condition).